Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein ...

BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...

The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...

Matthew J. Budoff, MD, comments on the role of statin therapy for dyslipidemia and shares considerations for appropriate selection and use. Transcript Deepak L. Bhatt, MD, MPH: I’m glad you brought in ...

ALAMEDA, Calif., January 20, 2026--(BUSINESS WIRE)--Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of ...

The ability of niacin to influence LDL-P is under active investigation and it appears that the beneficial effects of niacin extend beyond the traditional evaluation of the 'lipid profile.' Taken ...

Please provide your email address to receive an email when new articles are posted on . Evinacumab, a novel fully human monoclonal antibody against angiopoietin-like 3, reduced LDL by more than 50% ...